You just read:

First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Multiple Sclerosis Relapse

News provided by

Mallinckrodt Pharmaceuticals

May 23, 2017, 17:00 ET